Drugs.com Clinical Trial ResultsOriginal article
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis
Phase 2positivezumilokibartPositive
AI Analysis
Summary
AbbVie announced positive primary results from the Phase 2 APEX Part B study of zumilokibart in adults with moderate to severe atopic dermatitis. The dose-regimen-finding study highlights efficacy data for the investigational treatment.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Primary results from Phase 2 APEX Part B Dose-Regimen-Finding Study announced
Importance:7/10
Sentiment:
0.80
Phase 2 resultsatopic dermatitispositive datadose-regimen finding
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 30, 2026 9:09 PM